TY - JOUR
T1 - Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma
AU - Fujimura, Taku
AU - Sato, Yota
AU - Tanita, Kayo
AU - Lyu, Chinbing
AU - Kambayashi, Yumi
AU - Amagai, Ryo
AU - Otsuka, Atsushi
AU - Fujisawa, Yasuhiro
AU - Yoshino, Koji
AU - Matsushita, Shigeto
AU - Uchi, Hiroshi
AU - Yamamoto, Yuki
AU - Hata, Hiroo
AU - Funakoshi, Takeru
AU - Nonomura, Yumi
AU - Tanaka, Ryota
AU - Okuhira, Hisako
AU - Wada, Naoko
AU - Hashimoto, Akira
AU - Aiba, Setsuya
N1 - Publisher Copyright:
© 2019 Fujimura, Sato, Tanita, Lyu, Kambayashi, Amagai, Otsuka, Fujisawa, Yoshino, Matsushita, Uchi, Yamamoto, Hata, Funakoshi, Nonomura, Tanaka, Okuhira, Wada, Hashimoto and Aiba.
PY - 2019
Y1 - 2019
N2 - Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
AB - Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
KW - Baseline levels of CXCL5
KW - Melanoma
KW - Nivolumab
KW - Nivolumab and ipilimumab combined therapy
KW - Prediction of efficacy
UR - http://www.scopus.com/inward/record.url?scp=85064708367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064708367&partnerID=8YFLogxK
U2 - 10.3389/fmed.2019.00086
DO - 10.3389/fmed.2019.00086
M3 - Article
AN - SCOPUS:85064708367
SN - 2296-858X
VL - 6
JO - Frontiers in Medicine
JF - Frontiers in Medicine
IS - APR
M1 - 86
ER -
